Nemluvio Shortage: What Providers and Prescribers Need to Know in 2026

As prescribers increasingly incorporate Nemluvio (nemolizumab-ilto) into their treatment algorithms for prurigo nodularis and moderate-to-severe atopic dermatitis, a recurring pain point is emerging: patients are experiencing significant delays between prescription and first dose. This isn't a drug shortage in the traditional sense — Nemluvio supply from Galderma is stable — but it is a multifactorial access problem that clinicians need to understand and proactively address.

Current FDA Shortage Status for Nemluvio

As of 2026, Nemluvio is NOT on the FDA's Drug Shortages database (accessible at ashp.org/drug-shortages or fda.gov). Galderma has not issued any supply disruption notifications. The drug is manufactured using recombinant DNA technology in Chinese Hamster Ovary (CHO) cells, and production capacity appears adequate for current market demand.

That said, as prescriber adoption grows following the December 2024 expanded indication for atopic dermatitis — a condition affecting tens of millions of Americans — demand may increase significantly. Clinicians should be aware of potential capacity strain if prescribing volumes surge rapidly.

The Real Access Barriers Your Patients Face

The primary access barriers to Nemluvio in 2026 are administrative and financial, not supply-related:

1. Prior Authorization Requirements

Virtually all commercial insurance plans require prior authorization for Nemluvio, and most payer policies include step therapy requirements. For PN, payers typically require documented failure of topical corticosteroids and/or calcineurin inhibitors. For AD, policies often require failure of at least one other biologic (typically dupilumab as first-line) before approving Nemluvio.

Documentation requirements vary by payer but typically include: diagnosis confirmation with ICD-10 codes (L28.1 for PN; L20.0-L20.9 for AD), severity documentation (IGA score, EASI score, body surface area affected, symptom burden on quality of life), and treatment history showing inadequate response to prior therapies.

2. Specialty Pharmacy Enrollment Bottlenecks

Nemluvio is exclusively dispensed through specialty pharmacies via the GPS (Galderma Patient Services) program. Enrollment requires completing a multi-page form that includes prescriber information, patient information, insurance data, clinical documentation, and program elections (Quick Start, copay assistance, etc.). Incomplete forms are the most common cause of enrollment delays.

Best practice for your office: Designate a staff member as the Nemluvio enrollment coordinator. Ensure all sections of the enrollment form are completed before submission, including the patient authorization signature. Incomplete forms are returned and restart the clock.

3. New Drug Formulary Gaps

Because Nemluvio was only approved in late 2024, some commercial formularies — especially those with annual update cycles — may not have incorporated Nemluvio coverage criteria yet. Medicare plans are still developing coverage policies, and Medicaid coverage varies by state.

Tip: Before prescribing Nemluvio, have your staff verify whether the patient's specific plan has a Nemluvio policy in place. GPS benefit investigation can help surface this quickly. If coverage is unavailable, the Patient Assistance Program or Bridge Program may bridge the gap.

Galderma GPS Support Programs: What Clinicians Need to Know

Galderma Patient Services (GPS) for Nemluvio provides a suite of programs designed to minimize access barriers:

Quick Start: Provides the 60 mg loading dose plus additional refills to treatment-naïve, commercially insured patients while PA is pending. This is critical for patients with active, burdensome disease who cannot wait.

Copay Assistance: Commercially insured patients may pay as little as $0 per dose, up to $15,000/year in savings. Patients are auto-re-enrolled annually if still on therapy.

Bridge Program: For patients experiencing coverage gaps due to insurance changes, delayed re-authorization, or PA appeals.

Patient Assistance Program: For uninsured or underinsured patients who meet income criteria; medication provided at no cost.

Nurse Navigators: Available to support patients with injection training and adherence coaching, reducing burden on your office staff.

When to Consider Alternative Biologics

For patients where Nemluvio access is impossible or severely delayed, the following evidence-based alternatives are available:

Prurigo nodularis: Dupixent (dupilumab) is the only other FDA-approved biologic for PN. Off-label options include cyclosporine, methotrexate, and phototherapy (narrowband UVB).

Atopic dermatitis: Dupixent, Adbry (tralokinumab), Ebglyss (lebrikizumab), Rinvoq (upadacitinib), and Cibinqo (abrocitinib) are all FDA-approved alternatives.

How medfinder Supports Your Patients Through Access Challenges

When your patients are navigating specialty pharmacy enrollment, PA appeals, or coverage gaps, medfinder can help identify which pharmacies in their area can fill their prescriptions. Learn more at medfinder.com/providers or read our provider's guide to helping patients find Nemluvio for practical action steps.